Jan 08, 2020
Agenus Commences Phase 1 trial with AGEN1223
Dec 19, 2019
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
Nov 12, 2019
Agenus to Host R&D Day November 15, 2019
Nov 11, 2019
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
Nov 04, 2019
Agenus Provides Corporate Update with Third Quarter 2019 Financial Results
Sep 30, 2019
Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
Aug 08, 2019
Agenus Milestone Triggers $7.5M Payment
Aug 08, 2019
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 06, 2019
Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast
Jul 18, 2019
Agenus Appoints Don Vidic as Vice President and Head of Commercial
May 09, 2019
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
Apr 02, 2019
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
Mar 21, 2019
Agenus Announces Clinical Appointments
Mar 14, 2019
Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar 13, 2019
Agenus Milestone Triggers $7.5M Payment from Gilead
Mar 08, 2019
Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast
Feb 19, 2019
Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare
Feb 15, 2019
Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019
Jan 29, 2019
Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.
Jan 29, 2019
Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare